AAD 2026Abstract 72640
Enhanced effectiveness of guselkumab as first-line biologic therapy in psoriasis
real-world results over 84 weeks from the G-REAL study
Gerdes S, Hoffmann M, Segert MH, Ostendorf R, Groß D, Taut FJH, Scharfenberger L, Jacobsen S, Behrens J, Spindler N, von Kiedrowski R
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Psoriasis
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.802 · Not in PubMed: details from Crossref